TABLE 2.

Characteristics of patients at risk for IA in whom serum BG and GM was evaluated

CharacteristicProven IAProbable IAPossible IANo IATotal
No. of patients5332940
Age (yr)a48 (29-70)49 (32-70)33 (20-54)45 (18-70)44 (18-70)
Gender (M/F)b2/32/12/117/1223/17
No. (%) with underlying diseasec
    ALL2 (66.7)2 (5)
    AML2 (40)2 (66.7)1 (33.3)4 (13.8)9 (22.5)
    CLL1 (20)8 (27.5)9 (22.5)
    MM3 (10.34)3 (7.5)
    MDS1 (20)1 (33.3)1 (3.4)3 (7.5)
    NHL1 (20)8 (27.6)9 (22.5)
    HD4 (13.8)4 (10)
    SAA1 (3.4)1 (2.5)
No. (%) receiving steroids3 (60)3 (100)1 (33.3)6 (20.7)13 (32.5)
Mean duration of neutropenia (days)42.837.3343.622.4427.7
Range of duration of neutropenia (days)10-7027-5626-566-706-70
No. of episodes of antifungal therapy5 (100)3 (100)3 (100)12 (30)23 (57.5)
No. of samples (total)693639181325
No. of samples/episode13.81212.666.248.12
No.d (%) of positive episodes5 (100)2 (66)1 (33)3 (10.34)11 (27.5)
No. (%) of positive samples for BG35 (50.7)17 (47.2)12 (30.7)6 (3.3)64 (19.7)
No. (%) of positive samples for GM28 (40.6)13 (36.1)11 (28.2)6 (3.3)58 (17.8)
  • a Values in parentheses are ranges.

  • b M/F, male/female.

  • c ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CLL, Chronic lymphocytic leukemia; MM, Multiple myeloma; MDS, Myelodisplastic syndrome; NHL, Non-Hodgkin's lymphoma; HD, Hodgkin disease; SAA, Severe aplastic anemia.

  • d Values in parentheses are percentages of patients who received antifungal therapy.